Research ArticleInfectious Disease

Human IFNAR2 deficiency: Lessons for antiviral immunity

Science Translational Medicine  30 Sep 2015:
Vol. 7, Issue 307, pp. 307ra154
DOI: 10.1126/scitranslmed.aac4227

You are currently viewing the abstract.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Type I interferons in antiviral defense

Type I interferons have been shown in animal models to provide a critical antiviral defense, but supporting data in humans have been lacking. Now, Duncan et al. report the case of a child and a newborn sibling with a homozygous mutation in the high-affinity interferon-α/β receptor (IFNAR2), which prevented cells from responding to IFN-α/β. The previously healthy proband developed fatal encephalitis after exposure to the live attenuated measles, mumps, and rubella vaccine. Reconstituting the proband’s cells with IFNAR2 restored control of IFN-attenuated viruses. These data support an essential role for IFN-α/β in antiviral immunity.

Abstract

Type I interferon (IFN-α/β) is a fundamental antiviral defense mechanism. Mouse models have been pivotal to understanding the role of IFN-α/β in immunity, although validation of these findings in humans has been limited. We investigated a previously healthy child with fatal encephalitis after inoculation of the live attenuated measles, mumps, and rubella (MMR) vaccine. By targeted resequencing, we identified a homozygous mutation in the high-affinity IFN-α/β receptor (IFNAR2) in the proband, as well as a newborn sibling, that rendered cells unresponsive to IFN-α/β. Reconstitution of the proband’s cells with wild-type IFNAR2 restored IFN-α/β responsiveness and control of IFN-attenuated viruses. Despite the severe outcome of systemic live vaccine challenge, the proband had previously shown no evidence of heightened susceptibility to respiratory viral pathogens. The phenotype of IFNAR2 deficiency, together with similar findings in STAT2-deficient patients, supports an essential but narrow role for IFN-α/β in human antiviral immunity.

View Full Text